Evidence map›Paper›PMID 29946230›Full record

ArticleClinical proteomics2018

Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts.

Xinyan Wu, Muhammad Saddiq Zahari, Santosh Renuse, Nandini A Sahasrabuddhe, Raghothama Chaerkady, Min-Sik Kim, Mary Jo Fackler, Martha Stampfer, Edward Gabrielson, Saraswati Sukumar and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Clinical proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment.Journal of mammary gland biology and neoplasia · 2021
    Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Xinyan Wu *1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.
Muhammad Saddiq Zahari *1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.
Santosh Renuse *1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.
Nandini A Sahasrabuddhe1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.
Raghothama Chaerkady1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.
Min-Sik Kim1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.
Mary Jo Fackler5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Martha Stampfer7Division of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA USA.
Edward Gabrielson5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Saraswati Sukumar5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Akhilesh Pandey1Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD USA.ORCID 0000-0001-9943-6127

Funding

Understanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK · 1998 to 2019
$38.8M
The Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic TargetsU24CA210985 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2016 to 2020
$5.3M
Personalized Therapy of Hormone Refractory Breast CancerR01CA184165 · NCI · MAYO CLINIC ROCHESTER · PI PANDEY, AKHILESH · 2015 to 2019
$1.8M
Fourier Transform Orbitrap Fusion Lumos Tribrid Mass Spectrometer with ETDS10OD021844 · OD · JOHNS HOPKINS UNIVERSITY · PI PANDEY, AKHILESH · 2016 to 2016
$1.1M
NCI NIH HHS R01 CA184165NCI NIH HHS U24 CA210985NIH HHS S10 OD021844NINDS NIH HHS P50 NS038377
6 · The paper itself

Abstract

backgroundCancer-associated fibroblasts (CAFs) are one of the most important components of tumor stroma and play a key role in modulating tumor growth. However, a mechanistic understanding of how CAFs communicate with tumor cells to promote their proliferation and invasion is far from complete. A major reason for this is that most current techniques and model systems do not capture the complexity of signal transduction that occurs between CAFs and tumor cells.

methodsIn this study, we employed a stable isotope labeling with amino acids in cell culture (SILAC) strategy to label invasive breast cancer cells, MDA-MB-231, and breast cancer patient-derived CAF this has already been defined above cells. We used an antibody-based phosphotyrosine peptide enrichment method coupled to LC-MS/MS to catalog and quantify tyrosine phosphorylation-mediated signal transduction events induced by the bidirectional communication between patient-derived CAFs and tumor cells.

resultsWe discovered that distinct signaling events were activated in CAFs and in tumor epithelial cells during the crosstalk between these two cell types. We identified reciprocal activation of a number of receptor tyrosine kinases including EGFR, FGFR1 and EPHA2 induced by this bidirectional communication.

conclusionsOur study not only provides insights into the mechanisms of the interaction between CAFs and tumor cells, but the model system described here could be used as a prototype for analysis of intercellular communication in many different tumor microenvironments.

Indexed as

Breast cancerCarcinoma-associated fibroblastCo-cultureEpithelial cellMass spectrometryPhosphoproteomeSignaling crosstalkSILAC

Identifiers

PMID29946230
PMCPMC6003199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.